Ofloxacin vs tobramycin for the treatment of external ocular infection. Ofloxacin Study Group II.
A multicenter, double-masked, randomized clinical investigation was conducted comparing 0.3% ofloxacin and 0.3% tobramycin for topical treatment of external ocular infection. One drop (1.35 micrograms) of either test solution was instilled six times daily for 2 days and thereafter four times daily for the next 8 days. At the day 3 to 5 follow-up examination, the severity of signs and symptoms based on a clinical summary score of 10 key variables was reduced from baseline values significantly (P less than .05) more with ofloxacin (-6.4 +/- 4.37; mean +/- SD) than with tobramycin (-4.78 +/- 3.13); by day 11, the difference between the groups was no longer significant. At days 3 to 5 and day 11 examinations, clinical, microbiologic, and overall improvement rates were similar, with no significant differences seen between the groups. Ofloxacin was found as effective, safe, and comfortable as tobramycin in patients with external ocular infection and may provide earlier symptom relief.
Gwon
A
A
Allergan Pharmaceuticals, Irvine, Calif. 92713-9534.
D001762:Blepharitis / Q000188:drug therapy* / Q000382:microbiology; D015169:Colony Count, Microbial; D003228:Conjunctiva / Q000382:microbiology; D003234:Conjunctivitis, Bacterial / Q000188:drug therapy*; D003320:Corneal Ulcer / Q000188:drug therapy* / Q000382:microbiology; D004311:Double-Blind Method; D005143:Eyelids / Q000382:microbiology; D006801:Humans; D008828:Microbiological Techniques; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D014031:Tobramycin / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D009883:Ophthalmic Solutions; D015242:Ofloxacin; D014031:Tobramycin